Compositions and methods for modulating UTRN expression

• US 10,058,623 B2
• Filed: 05/16/2013
• Issued: 08/28/2018
• Est. Priority Date: 05/16/2012
• Status: Active Grant

• Current Assignee: The General Hospital Corporation (Mass General Brigham, Inc.)
• Original Assignee: The General Hospital Corporation (Mass General Brigham, Inc.), Translate Bio MA Inc. (Sanofi )
• Inventors: Krieg, Arthur M., Subramanian, Romesh, McSwiggen, James, Lee, Jeannie T.
• Primary Examiner(s): VIVLEMORE, TRACY ANN
• Application Number:
  US14/401,196
• Publication Number:
  US 20150099791A1
• Time in Patent Office: 1,930 Days
• Field of Search: None
• CPC Class Codes: A61K 47/54 the modifying agent being an organic compound
• CPC Class Codes: A61K 47/61 the organic macromolecular compound being a polysaccharide or a derivative thereof
• CPC Class Codes: A61K 47/64 Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent peptidic linkers A61K47/65
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 21/04 for myasthenia gravis
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C12N 15/113 Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing when used in plants C12N15/8218
• CPC Class Codes: C12N 2310/11 Antisense
• CPC Class Codes: C12N 2310/315 Phosphorothioates
• CPC Class Codes: C12N 2310/321 2'-O-R Modification
• CPC Class Codes: C12N 2310/3231 having an additional ring, e.g. LNA, ENA
• CPC Class Codes: C12N 2310/351 Conjugate

Abstract

Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of UTRN. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of UTRN. Methods for modulating expression of UTRN using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of UTRN.

Claims

1. A single stranded oligonucleotide produced by a process comprising:

synthesizing a single stranded oligonucleotide that;

(a) has a sequence 5′

-X-Y-Z, wherein X is any nucleotide, Y is a nucleotide sequence of 6 nucleotides in length that is not a seed sequence of a human microRNA, and Z is a nucleotide sequence of 5 to 8 nucleotides in length,

(b) is complementary with at least 8 consecutive nucleotides of a PRC2-associated region of a UTRN gene, wherein the PRC2-associated region is a region of the UTRN gene that has a sequence that occurs at a higher frequency in a sequencing reaction of products of an RNA-immunoprecipitation assay that employs an antibody that targets Ezh2 to immunoprecipitate RNA-associated PRC2 complexes from cells comprising the UTRN gene compared to a control sequencing reaction of products of a control RNA-immunoprecipitation assay that employs a control antibody; and

(c) is 12 to 15 nucleotides in length, wherein, during the synthesis,

at least one nucleotide incorporated into the oligonucleotide is a nucleotide analogue and/or a modified internucleotide linkage is incorporated between at least two nucleotides.

2. The single stranded oligonucleotide of claim 1, wherein the oligonucleotide does not comprise three or more consecutive guanosine nucleotides.

3. The single stranded oligonucleotide of claim 1, wherein the oligonucleotide does not comprise four or more consecutive guanosine nucleotides.

4. The single stranded oligonucleotide of claim 1, wherein at least one nucleotide of the oligonucleotide is a nucleotide analogue.

5. The single stranded oligonucleotide of claim 4, wherein the at least one nucleotide analogue results in an increase in Tm of the oligonucleotide in a range of 1 to 5°

C. compared with an oligonucleotide that does not have the at least one nucleotide analogue.

6. The single stranded oligonucleotide of claim 1, wherein at least one nucleotide of the oligonucleotide comprises a 2′

O-methyl.

7. The single stranded oligonucleotide of claim 1, wherein each nucleotide of the oligonucleotide comprises a 2′

O-methyl.

8. The single stranded oligonucleotide of claim 1, wherein the oligonucleotide comprises at least one ribonucleotide, at least one deoxyribonucleotide, or at least one bridged nucleotide.

9. The single strand oligonucleotide of claim 8, wherein the bridged nucleotide is a LNA nucleotide, a cEt nucleotide or a ENA modified nucleotide.

10. The single stranded oligonucleotide of claim 1, wherein each nucleotide of the oligonucleotide is a LNA nucleotide.

11. The single stranded oligonucleotide of claim 1, wherein the nucleotides of the oligonucleotide comprise alternating deoxyribonucleotides and 2′

-fluoro-deoxyribonucleotides.

12. The single stranded oligonucleotide of claim 1, wherein the nucleotides of the oligonucleotide comprise alternating deoxyribonucleotides and 2′

-O-methyl nucleotides.

13. The single stranded oligonucleotide of claim 1, wherein the nucleotides of the oligonucleotide comprise alternating deoxyribonucleotides and ENA nucleotide analogues.

14. The single stranded oligonucleotide of claim 1, wherein the nucleotides of the oligonucleotide comprise alternating deoxyribonucleotides and LNA nucleotides.

15. The single stranded oligonucleotide of claim 11, wherein the 5′

nucleotide of the oligonucleotide is a deoxyribonucleotide.

16. The single stranded oligonucleotide of claim 1, wherein the nucleotides of the oligonucleotide comprise alternating LNA nucleotides and 2′

-O-methyl nucleotides.

17. The single stranded oligonucleotide of claim 16, wherein the 5′

nucleotide of the oligonucleotide is a LNA nucleotide.

18. The single stranded oligonucleotide of claim 1, wherein the nucleotides of the oligonucleotide comprise deoxyribonucleotides flanked by at least one LNA nucleotide on each of the 5′

and 3′

ends of the deoxyribonucleotides.

19. The single stranded oligonucleotide of claim 1, further comprising phosphorothioate internucleotide linkages between at least two nucleotides.

20. The single stranded oligonucleotide of claim 19, further comprising phosphorothioate internucleotide linkages between all nucleotides.

21. The single stranded oligonucleotide of claim 1, wherein the nucleotide at the 3′

position of the oligonucleotide has a 3′

hydroxyl group.

22. The single stranded oligonucleotide of claim 1, wherein the nucleotide at the 3′

position of the oligonucleotide has a 3′

thiophosphate.

23. The single stranded oligonucleotide of claim 1, further comprising a biotin moiety conjugated to the 5′

nucleotide.

26. A composition comprising a single stranded oligonucleotide of claim 1 and a carrier.

27. A composition comprising a single stranded oligonucleotide of claim 1 in a buffered solution.

28. A composition of claim 26, wherein the oligonucleotide is conjugated to the carrier.

29. The composition of claim 28, wherein the carrier is a peptide.

30. The composition of claim 28, wherein the carrier is a steroid.

31. A pharmaceutical composition comprising a composition of claim 26 and a pharmaceutically acceptable carrier.

32. A kit comprising a container housing the composition of claim 26.

24. A single stranded oligonucleotide produced by a process comprising:

synthesizing a single stranded oligonucleotide that;

(a) comprises a region of complementarity that is complementary with at least 8 consecutive nucleotides of a PRC2-associated region of a UTRN gene, wherein the PRC2 associated-region of a UTRN gene, wherein the PRC2-associated region is a region of the UTRN gene that has a sequence that occurs at a higher frequency in a sequencing reaction of products of an RNA-immunoprecipitation assay that employs an antibody that targets Ezh2 to immunoprecipitate RNA-associated PRC2 complexes from cells comprising the UTRN gene compared to a control sequencing reaction of products of a control RNA-immunoprecipitation assay that employs a control antibody;

(b) is between 12 and 15 nucleotides in length and has at least one of;

i) a sequence that is 5′

X-Y-Z, wherein X is any nucleotide and wherein X is anchored at the 5′

end of the oligonucleotide, Y is a nucleotide sequence of 6 nucleotides in length that is not a human seed sequence of a microRNA, and Z is a nucleotide sequence of 5 to 8 nucleotides in length;

ii) a sequence that does not comprise three or more consecutive guanosine nucleotides;

iii) a sequence that is complementary to a PRC2-associated region that encodes an RNA that forms a secondary structure comprising at least two single stranded loops; and

/or

iv) a sequence that has greater than 60% G-C content,

wherein, during the synthesis, at least one nucleotide incorporated into the oligonucleotide is a nucleotide analogue and/or a modified internucleotide linkage is incorporated between at least two nucleotides.

25. The single stranded oligonucleotide of claim 24, wherein the oligonucleotide has the sequence 5′

X-Y-Z.